These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9858218)

  • 21. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
    Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
    Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
    Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
    Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.
    Juliusson G; Christiansen I; Hansen MM; Johnson S; Kimby E; Elmhorn-Rosenborg A; Liliemark J
    J Clin Oncol; 1996 Jul; 14(7):2160-6. PubMed ID: 8683250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Fridrik MA; Jäger G; Baldinger C; Krieger O; Chott A; Bettelheim P
    Ann Hematol; 1997 Jan; 74(1):7-10. PubMed ID: 9031608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma.
    Cervetti G; Galimberti S; Cecconi N; Caracciolo F; Petrini M
    J Chemother; 2004 Aug; 16(4):388-91. PubMed ID: 15332715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
    Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
    Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenström's macroglobulinemia.
    Aslan DL; Peterson BA; Long-Tsai M; Eastlund T
    Transfusion; 2006 Jan; 46(1):90-4. PubMed ID: 16398735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature.
    Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Hellmann A
    Med Sci Monit; 2000; 6(4):740-5. PubMed ID: 11208402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
    Morton J; Taylor K; Bunce I; Eliadis P; Rentoul A; Moore D; Kelly C; Wright S; Bashford J; Rodwell R; Rooney K; Mulligan S; Firkin F; Dodds A; Parkin J; Lowenthal R; Kimber R; Frost T; Grigg A; Goldstein D; Stone J; Lee N
    Br J Haematol; 1996 Oct; 95(1):110-5. PubMed ID: 8857946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
    Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
    Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
    Dimopoulos MA; Weber DM; Kantarjian H; Keating M; Alexanian R
    Ann Oncol; 1994 Mar; 5(3):288-9. PubMed ID: 7514439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
    Robak T; Góra-Tybor J
    Neoplasma; 2001; 48(3):203-7. PubMed ID: 11583290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
    Dimopoulos MA; Weber D; Delasalle KB; Keating M; Alexanian R
    Ann Oncol; 1995 Jan; 6(1):49-52. PubMed ID: 7710983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
    Lewandowski K; Halaburda K; Hellmann A
    Leuk Lymphoma; 2002 Feb; 43(2):361-3. PubMed ID: 11999570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.